S. Mulla

1.5k total citations · 1 hit paper
9 papers, 954 citations indexed

About

S. Mulla is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hepatology. According to data from OpenAlex, S. Mulla has authored 9 papers receiving a total of 954 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Hepatology. Recurrent topics in S. Mulla's work include Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Lung Cancer Treatments and Mutations (2 papers). S. Mulla is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (2 papers), Colorectal Cancer Treatments and Studies (2 papers) and Lung Cancer Treatments and Mutations (2 papers). S. Mulla collaborates with scholars based in Canada, United States and China. S. Mulla's co-authors include Joseph Beyene, Zhen Han, Sarah D. McDonald, Stephen D. Walter, Matthias Briel, Claudio Vera, François Lamontagne, Xin Sun, Jason W. Busse and Edward J. Mills and has published in prestigious journals such as BMJ, Annals of Oncology and Archives of Disease in Childhood.

In The Last Decade

S. Mulla

7 papers receiving 935 citations

Hit Papers

Overweight and obesity in mothers and risk of preterm bir... 2010 2026 2015 2020 2010 100 200 300 400

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Mulla Canada 6 340 295 194 149 145 9 954
Lindsay Blake United States 17 185 0.5× 114 0.4× 185 1.0× 68 0.5× 95 0.7× 64 905
Anna Palatnik United States 16 420 1.2× 367 1.2× 236 1.2× 19 0.1× 108 0.7× 105 849
Lucie Opatrny Canada 14 104 0.3× 64 0.2× 118 0.6× 62 0.4× 45 0.3× 28 938
Lois Donovan Canada 29 1.5k 4.5× 587 2.0× 261 1.3× 48 0.3× 383 2.6× 85 2.7k
TR Einarson Canada 13 78 0.2× 346 1.2× 337 1.7× 71 0.5× 109 0.8× 38 1.1k
Ian Greer United Kingdom 16 484 1.4× 406 1.4× 183 0.9× 25 0.2× 98 0.7× 31 1.7k
Sonia M. Grandi Canada 15 363 1.1× 306 1.0× 241 1.2× 12 0.1× 136 0.9× 63 1.3k
Tara Gurung United Kingdom 14 255 0.8× 155 0.5× 129 0.7× 59 0.4× 70 0.5× 27 778
Malia S. Q. Murphy Canada 18 282 0.8× 277 0.9× 101 0.5× 23 0.2× 151 1.0× 69 907
Soheir Adam United States 17 33 0.1× 168 0.6× 179 0.9× 116 0.8× 120 0.8× 56 1.4k

Countries citing papers authored by S. Mulla

Since Specialization
Citations

This map shows the geographic impact of S. Mulla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Mulla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Mulla more than expected).

Fields of papers citing papers by S. Mulla

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Mulla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Mulla. The network helps show where S. Mulla may publish in the future.

Co-authorship network of co-authors of S. Mulla

This figure shows the co-authorship network connecting the top 25 collaborators of S. Mulla. A scholar is included among the top collaborators of S. Mulla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Mulla. S. Mulla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

9 of 9 papers shown
3.
Toh, Han Chong, Philippe Merle, Kaoru Tsuchiya, et al.. (2020). O-8 Atezolizumab + bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150. Annals of Oncology. 31. 234–234. 12 indexed citations
4.
Gogas, Helen, Brigitte Dréno, James Larkin, et al.. (2020). Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study. Annals of Oncology. 32(3). 384–394. 71 indexed citations
6.
Bansal, Sanjay, Suzanne Davison, Sarah Tizzard, et al.. (2014). Treatment of chronic viral hepatitis C in children and adolescents: UK experience. Archives of Disease in Childhood. 99(6). 505–510. 15 indexed citations
7.
Akl, Elie A., Matthias Briel, John J. You, et al.. (2012). Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 344(may18 1). e2809–e2809. 231 indexed citations
8.
McDonald, SD, Zhen Han, S. Mulla, & Joseph Beyene. (2011). Overweight and Obesity in Mothers and Risk of Preterm Birth and Low Birth Weight Infants. Obstetric Anesthesia Digest. 31(3). 158–159. 4 indexed citations
9.
McDonald, Sarah D., et al.. (2010). Overweight and obesity in mothers and risk of preterm birth and low birth weight infants: systematic review and meta-analyses. BMJ. 341(jul20 1). c3428–c3428. 471 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026